Agomab Therapeutics NV has completed its initial public offering, securing approximately $200 million in gross proceeds before underwriting fees and other offering-related expenses, the company said in a statement. The proceeds figure reflects the total raised from the sale of American Depositary Shares prior to the deduction of fees.
The Belgium-headquartered, clinical-stage biopharmaceutical company offered 12.5 million ADSs at $16.00 per share. Each ADS corresponds to one common share of Agomab. Trading of the ADSs commenced on February 6, 2026 on the NASDAQ Global Select Market under the ticker symbol "AGMB."
Regulatory clearance for the offering was completed when the Securities and Exchange Commission declared the company’s registration statement effective on January 30, 2026. The offering was managed by a syndicate of joint book-running managers: J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen.
Agomab describes itself as a developer of therapies for immunology and inflammatory diseases, with a particular focus on chronic fibrotic conditions. According to the company, its clinical-stage product candidates are designed to engage established biological pathways using validated approaches intended to increase therapeutic efficacy while minimizing systemic toxicities.
From a capital-formation perspective, the offering structure and participants are now on record: 12.5 million ADSs sold at $16.00 each, producing roughly $200 million in gross proceeds before customary underwriting fees and expenses, and overseen by a book-running group of global and regional investment banks. The SEC effectiveness date and the subsequent start of trading on NASDAQ complete the transactional milestones disclosed by the company.
The company’s stated scientific approach emphasizes targeted, pathway-based strategies that aim to balance potency and safety, noting an explicit objective of reducing systemic toxicities while pursuing improved efficacy. Agomab’s corporate and clinical disclosures in the offering statement underpin the facts above; additional operational or financial outcomes following the offering were not included in the company statement.
Clear summary: Agomab concluded an IPO that sold 12.5 million ADSs at $16 per share, raising about $200 million in gross proceeds before fees, began NASDAQ trading as AGMB on February 6, 2026, and listed a group of major banks as joint book-runners after the SEC declared the registration effective on January 30, 2026. The company develops immunology and inflammatory disease therapies with an emphasis on chronic fibrotic conditions and pathway-targeted candidates intended to limit systemic toxicities.